Insulet Corp. closed 7.87% below its 52-week high of $289.46, which the company achieved on February 7th.

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S.

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Learn more about whether Koninklijke Philips N.V. or Insulet Corporation is a better investment based on AAII's A+ Investor ...